Why Oncology Analytics?

In the US, anti-cancer drug costs have increased over the past five years by 88% to $44B, driven primarily by availability and favorable reimbursement of new medicines. By 2021, global cancer drugs expenditures are expected to exceed $147B.

The Oncology Landscape

As treatment options and costs continue to rise, health plans, providers and patients face a collective challenge when trying to determine the best course of treatment.

Health PlanToday’s innovation driven climate puts health plans in the difficult position of determining how best to judge the cost/value ratio for the constant influx of new and emerging cancer treatments. As a result, health plans must address how to build scalable, internal oncology-specific expertise and processes, which can quickly evaluate treatment options across a multitude of cancer diagnoses.

ProviderDrug and treatment innovations across cancer types, such as immunotherapy, hold great promise for the future evolution of cancer treatment and care. However, innovation can also be disruptive, as the growing number of treatment options, combinations and additional lines of therapy simultaneously increases the complexity the oncologist faces in making an evidence-based determination for how to best treat a patient’s cancer.

PatientsThe changing oncology landscape in the U.S. healthcare market has real consequences for patients – the people for whom the decisions health plans and providers make have the greatest impact. Depending on the patient’s insurance plan, the rising cost of cancer treatment, may significantly increase out-of-pocket costs, which can potentially lead to reduced adherence to their care plan.

Why Oncology Analytics?

Evidence Based. Results Driven. Patient Focused.

Our founder, Dr. Marc Fishman, a hematologist, oncologist and patient advocate, recognized that the rising costs and complexity of cancer treatment was compromising the ability for oncologists to make comprehensive, evidenced-based decisions for their patients’ treatment.

Oncology Analytics believes that when building the optimal treatment plan, cost and quality are not mutually exclusive – and that doing the “right thing” requires a consistent process for evaluating the efficacy, toxicity and costs of treatment options, to put the patient in a position to achieve the best possible outcome.

Our board-certified oncologists, radiation oncologists, hematologists, and pharmacists have operationalized protocols that cover all cancer diagnoses. These protocols are based on evidence-based guidelines from nationally recognized authorities such as NCCN, ASCO and others.

Oncology Analytics understands the complexity involved in the management of cancer treatment options, due to the rapid pace of research and new drug introductions, which change the oncology landscape on a daily basis. We are committed to the ongoing review and analysis of oncology treatments, their outcomes and adverse effects.